Ганьшина Инна Петровна
Russian Cancer Research Center NN Blokhin · 96 works · 184 citations · h-index 5
Top works
- Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study
- The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
- Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
- Assessment of the receptor status in primary breast cancer with synchronous loco regional metastases: prognostic and clinical role?
- P26 HER-2 overexpressed breast cancer and brain metastases
- Abstract RF02-03: Trastuzumab deruxtecan (T-DXd) in combination with anastrozole or fulvestrant in patients with HER2-low HR+ advanced/metastatic breast cancer: a Phase 1b, open-label, multicenter, dose-expansion study (DESTINY-Breast08)
- The effectiveness, safety and economic rationality of the neoadjuvant chemotherapy with biosimilar of Trastuzumab in HER2+ breast cancer in Russian clinical practice.
- Efficacy and safety of cisplatin and paclitaxel (PlaTax regimen) in the neoadjuvant treatment of patients with stage II–III triple-negative breast cancer
- Clinical and radiological evaluation the effectiveness of preoperative systemic therapy in different biological subtypes of breast cancer stages T1-3N0-1M0
- The consensus on the prevention and correction of rash in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
- Dual HER2 blockade with pertuzumab+trastuzumab on the eve of a new era in the treatment of HER2-positive breast cancer
- The efficacy of neoadjuvant chemotherapy and survival in older patients with stages II to III triple-negative breast cancer
- Role of clustered amplification as a marker for a special sensitivity to neoadjuvant anti-HER2 therapy with trastuzumab in patients with stage II-III breast cancer
- Russian multicenter experience of using talazoparib in the treatment of patients with BRCA-associated metastatic breast cancer
- CHARACTERISTICS OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH AGGRESSIVE BIOLOGICAL SUBTYPES OF STAGE II–III BREAST CANCER. ORIGINAL STUDY
- Ribociclib for the treatment of hormone-positive HER2-negative breast cancer
- ASSOCIATION OF NKT- AND ACTIVATED CD25+ PERIPHERAL BLOOD LYMPHOCYTES WITH DISEASE FREE AND OVERALL SURVIVAL OF TRIPLE NEGATIVE BREAST CANCER PATIENTS
- Abstract P3-07-23: Defendor Special: Primary empegfilgrastim prophylaxis (prolonged G-CSF) for optimal treatment outcomes in high risk early breast cancer cohort. The interim analysis
- The effectiveness and safety of eribulin therapy in HR-positive HER2-negative metastatic breast cancer post-CDK4/6 inhibitor therapy in Russian clinical practice.
- Clinical and morphological aspects of neoadjuvant chemotherapy efficacy in patients with aggressive luminal HER2-negative breast cancer